BioSpace News Archive

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders

Extension of Partnership Leverages Automation to Support Central Pharmacy Operations and Patient Care Initiatives

BioTrace Medical, Inc., the leader in innovative temporary pacing technology, today announced the company’s Tempo® Lead has obtained CE Mark certification in Europe for use in cardiac procedures requiring temporary intracardiac pacing.

Columbia Care Inc. (“Columbia Care”, or the “Company”) (NEO: CCHW), today announced preliminary revenue and gross profit results for the quarter ended March 31, 2019, as well as the year ended December 29, 2018.

Bridgecom, provider of the standardized colorectal cancer (CRC) screening outreach program to accelerate patient compliance, announced today its acceptance as a corporate associate member of the National Colorectal Cancer Roundtable (NCCRT)

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today provided an update to stockholders regarding the Company’s rights offering and the key dates and terms relative to the offering.

Sixth pharma partner to internalize the Adimab platform

Adimab, LLC, the leading provider of antibody discovery and optimization technology, announced the expansion of an earlier multi-target research agreement with Regeneron Pharmaceuticals.

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced the expansion of an earlier partnership with Novartis.

Neuropore Therapies, Inc. announced that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34.